Innovation at Work
New Mexico

Total Direct and Indirect Economic Output of the Biopharmaceutical Sector
$3 billion

Total Employment Supported by the Biopharmaceutical Sector
14,231

New Mexico adults living with arthritis
22%

Total NIH Award Funding (FY17)
$100 million

Local Perspective: Albuquerque, NM

"I support research because in our modern day society knowledge is power. Through research we are able to gain power over disease and make progressions towards a healthier community. Our members of Congress should support research because that is the only way to further our knowledge base to expand our healthful possibilities."

Katelyn Burd, Arthritis Foundation advocate

A majority of Americans agree that even if it brings no immediate benefits, basic scientific research that advances the frontiers of knowledge is necessary and should be supported by the federal government.

Research in the Land of Enchantment

University of New Mexico (UNM), Albuquerque, NM

In a PCORI funded study, Researchers at the University of New Mexico are comparing the effectiveness of frequently prescribed medications for bipolar disorder. The retrospective study holds promise for choosing the best treatment for this public health condition.

AbbVie, Las Cruces and Albuquerque, NM

AbbVie is conducting phase III clinical trials to test the safety and effectiveness of a new small molecule medication to treat arthritis, a disease that affects over 50 million Americans. The treatment is intended for patients who have tried the standard treatment, but have experienced limited success and still suffer from the debilitating symptoms of arthritis.

Lovelace Respiratory Research Institute (LRRI), Albuquerque, NM

Nearly 64% of HIV-infected patients develop respiratory symptoms, with 21% developing chronic obstructive pulmonary disease (COPD). National Institutes of Health (NIH)-funded researchers at LRRI are investigating the role of a specific HIV protein in the development of COPD, which could lead to preventative and therapeutic interventions for this high-risk population.

SOURCES: NATIONAL INSTITUTES OF HEALTH (NIH), PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA), CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), A RESEARCH!AMERICA SURVEY OF U.S. ADULTS CONDUCTED IN PARTNERSHIP WITH ZOGBY ANALYTICS IN JANUARY 2017, AGENCY FOR HEALTHCARE RESEARCH AND QUALITY (AHRQ), CLINICALTRIALS.GOV.